XBI is an exchange-traded fund — it holds a basket of underlying assets rather than being a single operating company.
Company fundamentals like P/E, revenue, EPS and profit margins don't apply to a fund — its value comes from the assets it holds, not its own earnings. Use the price chart, options and model forecast below for fund-level analysis.
An institutional-grade, numbers-driven thesis on XBI — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates State Street SPDR S&P Biotech ETF (XBI) 58/100 with a 12-month base-case forecast of $209.44 — +30.5% versus the current price of $160.46. State Street SPDR S&P Biotech ETF trades at $160.46 in the Financial Services sector, with a market capitalisation of $8.51B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for XBI is $209.44, implying +30.5% versus the current price. The model's 12-month scenario range runs from $184.32 (bear) to $248.44 (bull), with a base case of $209.44.
XBI currently carries a TradersQuant composite score of 58/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Hold". Our 12-month price target of $209.44 implies +30.5% from $160.46. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for XBI is $209.44, about +30.5% versus the latest price of $160.46. Consensus is based on 1 analysts.
TradersQuant's 12-month model forecast for XBI is a base case of $209.44, ranging from $184.32 (bear) to $248.44 (bull), an expected return of +30.5%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for XBI over the next 12 months is $209.44 in the base case (bear $184.32, bull $248.44), versus today's price of $160.46. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for XBI — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates XBI's fair value at $206.63, implying +28.8% of expected upside versus the current price.
State Street SPDR S&P Biotech ETF does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
